The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient characteristics, treatment patterns and early trends of lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617) use by US urologists and oncologists.
 
Jennifer Nguyen
Employment - Novartis
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
Jeetvan Patel
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Barinder Kang
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Channing Yu
Employment - Daiichi Sankyo; Novartis
Stock and Other Ownership Interests - Daiichi Sankyo; Novartis
Patents, Royalties, Other Intellectual Property - Co-inventor on patent WO2013138585 A1 / US20150044676
 
Amrita Sawhney
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Mark Fallick
Employment - Myovant Sciences; Novartis
Stock and Other Ownership Interests - Myovant Sciences; Novartis
 
Magdaliz Gorritz
Research Funding - Amgen (Inst); AstraZeneca (Inst); Lilly (Inst); Novartis (Inst); Otsuka (Inst); Takeda (Inst); Travere Therapeutics (Inst)
 
Chi-Chang Chen
Research Funding - Novartis (Inst)
 
Queenie Paltanwale
Research Funding - Novartis (Inst)
 
Kainan Sun
Research Funding - Novartis (Inst)
 
Neal D. Shore
Employment - GenesisCare
Leadership - Alessa Therapeutics; Photocure
Stock and Other Ownership Interests - Alessa Therapeutics; Photocure
Consulting or Advisory Role - Abbvie; Accord Research; AIkido Pharma; Amgen; Antev; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Aura Biosciences; Bayer; Bioprotect; Bristol-Myers Squibb/Sanofi; CG Oncology; Clarity Pharmaceuticals; Dendreon; Exact Imaging; FerGene; Ferring; Fize Medical; Genesis Cancer Care; Genzyme; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Minomic; Myriad Genetics; Novartis; Peerview; Pfizer; Photocure; PlatformQ Health; Promaxo; Propella Therapeutics; Protara Therapeutics; Sanofi; Speciality Networks; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tolmar; Urogen pharma
Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; SeaGen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow
Expert Testimony - Ferring